These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8791944)

  • 1. Review article: renal circulatory changes in cirrhosis--pathogenesis and therapeutic prospects.
    Forrest EH; Jalan R; Hayes PC
    Aliment Pharmacol Ther; 1996 Jun; 10(3):219-31. PubMed ID: 8791944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem.
    Arroyo V; Jiménez W
    J Hepatol; 2000; 32(1 Suppl):157-70. PubMed ID: 10728802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac involvement in liver cirrhosis.
    Gatta A; Merkel C; Sacerdoti D; Angeli P
    Ann Ital Med Int; 1993; 8(4):244-7. PubMed ID: 8161481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review: the controversy over the pathophysiology of ascites formation in cirrhosis.
    Wong F; Girgrah N; Blendis L
    J Gastroenterol Hepatol; 1997 Jun; 12(6):437-44. PubMed ID: 9195401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LEFT ventricular function assessed by echocardiography in cirrhosis: relationship to systemic hemodynamics and renal dysfunction.
    Nazar A; Guevara M; Sitges M; Terra C; Solà E; Guigou C; Arroyo V; Ginès P
    J Hepatol; 2013 Jan; 58(1):51-7. PubMed ID: 22989573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.
    Angeli P; Volpin R; Piovan D; Bortoluzzi A; Craighero R; Bottaro S; Finucci GF; Casiglia E; Sticca A; De Toni R; Pavan L; Gatta A
    Hepatology; 1998 Oct; 28(4):937-43. PubMed ID: 9755229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal hemodynamics in patients with cirrhosis: relationship with ascites and liver failure.
    Moreau R; Gaudin C; Hadengue A; Braillon A; Roulot D; Bacq Y; Lebrec D
    Nephron; 1993; 65(3):359-63. PubMed ID: 8289984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis of ascites in cirrhosis and portal hypertension.
    Heneghan MA; Harrison PM
    Med Sci Monit; 2000; 6(4):807-16. PubMed ID: 11208415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The pathophysiology of ascites formation in cirrhosis of the liver].
    Benjaminov FS
    Harefuah; 2002 Aug; 141(8):721-5, 760. PubMed ID: 12222138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of renal sodium and water excretion in the nephrotic syndrome and cirrhosis of the liver.
    Jespersen B
    Dan Med Bull; 1997 Apr; 44(2):191-207. PubMed ID: 9151012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure.
    Fernandez-Seara J; Prieto J; Quiroga J; Zozaya JM; Cobos MA; Rodriguez-Eire JL; Garcia-Plaza A; Leal J
    Gastroenterology; 1989 Nov; 97(5):1304-12. PubMed ID: 2676683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of ascites formation.
    Cárdenas A; Bataller R; Arroyo V
    Clin Liver Dis; 2000 May; 4(2):447-65. PubMed ID: 11232200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of nitric oxide inhibition by methylene blue in cirrhotic patients with ascites.
    Kalambokis G; Economou M; Fotopoulos A; Bokharhii JA; Christos P; Paraskevi K; Konstantinos P; Katsaraki A; Tsianos EV
    Dig Dis Sci; 2005 Oct; 50(10):1771-7. PubMed ID: 16187171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis and treatment of ascites in hepatic cirrhosis.
    Gentilini P; La Villa G; Romanelli RG; Foschi M; Laffi G
    Cardiology; 1994; 84 Suppl 2():68-79. PubMed ID: 7954548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment.
    Wong F; Raina N; Richardson R
    Gut; 2010 Mar; 59(3):381-6. PubMed ID: 19710033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoid type 1 receptor antagonism delays ascites formation in rats with cirrhosis.
    Domenicali M; Caraceni P; Giannone F; Pertosa AM; Principe A; Zambruni A; Trevisani F; Croci T; Bernardi M
    Gastroenterology; 2009 Jul; 137(1):341-9. PubMed ID: 19208344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of neonatal capsaicin treatment on haemodynamics and renal function in cirrhotic rats.
    Li Y; Song D; Zhang Y; Lee SS
    Gut; 2003 Feb; 52(2):293-9. PubMed ID: 12524416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal effects of natriuretic peptide receptor blockade in cirrhotic rats with ascites.
    Angeli P; Jiménez W; Arroyo V; Mackenzie HS; Zhang PL; Clària J; Rivera F; Brenner BM; Rodés J
    Hepatology; 1994 Oct; 20(4 Pt 1):948-54. PubMed ID: 7927237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Liver cirrhosis: pathogenesis of ascites and disturbance of renal function].
    Toledo C; Ginés P; Arroyo V
    Rev Med Chil; 1992 Feb; 120(2):180-7. PubMed ID: 1340557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis of ascites in cirrhosis.
    Ginès P; Fernández-Esparrach G; Arroyo V; Rodés J
    Semin Liver Dis; 1997; 17(3):175-89. PubMed ID: 9308123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.